{{Rsnum
|rsid=10497845
|Chromosome=2
|position=200033174
|Orientation=plus
|GMAF=0.1253
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 5.3 | 94.7
| HCB | 0.0 | 40.1 | 59.9
| JPT | 1.8 | 28.3 | 69.9
| YRI | 0.7 | 21.8 | 77.6
| ASW | 0.0 | 17.5 | 82.5
| CHB | 0.0 | 40.1 | 59.9
| CHD | 3.7 | 29.4 | 67.0
| GIH | 0.0 | 8.9 | 91.1
| LWK | 0.9 | 15.5 | 83.6
| MEX | 10.3 | 31.0 | 58.6
| MKK | 0.0 | 7.7 | 92.3
| TSI | 1.0 | 2.9 | 96.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10497845
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.08, combined P value= 2.83E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470226
}}

{{PMID Auto
|PMID=17903300
|Title=Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10497845
|overall_frequency_n=15
|overall_frequency_d=128
|overall_frequency=0.117188
|n_genomes=12
|n_genomes_annotated=0
|n_haplomes=12
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}